Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioblastoma × tivozanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 5 Neoplasm Metastasis 2 Triple Negative Breast Neoplasms 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Liver Neoplasms 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms 1

Interventions

Temozolomide 140 Bevacizumab 80 Radiotherapy 69 Magnetic Resonance Spectroscopy 22 Radiation 18 Irinotecan 18 pembrolizumab 17 Lomustine 16 Carmustine 15 Surgical Procedures, Operative 13 Nivolumab 11 Erlotinib Hydrochloride 11 sargramostim 9 Thalidomide 9 Specimen Handling 9 Chemotherapy, Adjuvant 9 Aminolevulinic Acid 9 Carboplatin 8 Cilengitide 7 Sunitinib 6 Immunoglobulin G 6 Etoposide 6 Disulfides 6 Cyclophosphamide 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Radiotherapy, Intensity-Modulated 5 Radiosurgery 5 Metformin 5 Imatinib Mesylate 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01846871 2019-01-08

Tivozanib for Recurrent Glioblastoma

Massachusetts General Hospital

Phase 2 Completed

10 enrolled 13 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡